PDCD1 and Miyoshi myopathy: However, single‐agent therapy with PD‐1 inhibitors fails to induce significant clinical responses in a phase 1b study,16 suggesting that PD‐1 blockade alone is insufficient to reinvigorate a clinically meaningful anti‐MM immunity.